Kornimate/medical-research-clean huggingface dataset:
pilot and feasibility study of the imaging potential of ec17: intraoperative folate-fluorescein conjugate (ec17) lung cancer (ca)

Conditions: Lung and Pleural Malignancies; Neoplasms; Nodules; Adenocarcinoma

Summary: the goal of this study is to perform imaging of patient's tumors while the chest is open and the tumor is being removed. according to the world health organization, lung cancer is the most common cause of cancer-related death in men and women, and is responsible for 1.3 million deaths worldwide annually as of 2004. surgery remains the best option for patients presenting with operable stage i or ii cancers, however the five year survival rate for these candidates remains at a dismal 53% for stage i and 32% for stage ii. the high rates of recurrence suggest that surgeons are unable to completely detect and remove primary tumor nodules in a satisfactory manner as well as lingering metastases in sentinel lymph nodes. by ensuring a negative margin through imaging during surgery it would be possible for us to improve the rates of recurrence free patients and thus overall survival. thoracic malignancies are the ideal disease to investigate intra-operative imaging. over 85% of lung and pleural malignancies express folate receptor alpha (fra). it is important to note that fra is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. thus, the false positive detection rate is expected to be extremely low. a group well known to us in the netherlands has completed a pilot study utilizing a folate-fluorescein isothiocyanate (folate-fitc) conjugate in 12 patients with ovarian cancer. another group of investigators in mayo have subsequently performed this study on 20 more patients without any serious adverse events (personal communication). they report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). all side effects reversed when the injection was halted. patients with a history of allergic reactions to insect bites should not participate (fluorescein is derived from the firefly insect, folate is an essential vitamin).

this will identify the margins and the lymph nodes that may have cancer cells during cancer surgery

Eligibility criteria:
inclusion criteria: * adult patients over 18 years of age * patients presenting with a lung or pleural nodule or mass presumed to be resectable on pre-operative assessment * good operative candidate * subject capable of giving informed consent and participating in the process of consent exclusion criteria: * pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hcg) within 72 hours of surgery * patients with a history of anaphylactic reactions to folate-fitc or insects * at-risk patient populations: * homeless patients * patients with drug or alcohol dependence * children and neonates * patients unable to participate in the consent process
dose-response relationship of phototherapy for hyperbilirubinaemia using diodes: is there a "saturation point"

Conditions: Neonatal Hyperbilirubinemia

Summary: background: using light emitting diodes (led's) during conventional phototherapy it is possible to reduce the distance from light source to infant, thereby increasing light irradiance. objective: to examine the relation between light irradiance and the rate of decrease in total serum bilirubin concentration (tsb) and to see if the investigators can identify a "saturation point", i.e. an irradiation level above which there is no further decrease in tsb. design: prospective randomised study. setting: neonatal intensive care unit, pediatric department, aalborg hospital, aarhus university hospital, denmark. material and method: 151 infants with gestational age ≥ 33 weeks and uncomplicated hyperbilirubinaemia are randomised to one of 4 different distances from phototherapy device to mattress (20, 29, 38 and 47 cm). tsb is measured before and after 24 hours of phototherapy and irradiance every 8th hour. main outcome measure is 24 hours decrease of tsb expressed in percent (∆ tsb0-24 (%)).


Eligibility criteria:
inclusion criteria: * gestational age ≥ 33 weeks * uncomplicated neonatal hyperbilirubinemia exclusion criteria: * \< 33 weeks * infants in incubators

Keywords: neonates hyperbilirubinemia phototherapy light irradiance saturation point
service dog training program for military veterans with ptsd

Conditions: Post Traumatic Stress Disorder

Summary: post-traumatic stress disorder (ptsd), an invisible wound of war, affects approximately 20%1 of the 18.5 million u.s. veterans and places them at higher risk for impaired biopsychosocial functioning. ptsd symptom severity (ptsdss) is significantly correlated with stress and psychosocial consequences of inability to regulate emotions, control impulsive behaviors, and function within family and society. alarming veteran ptsd rates and its insidious effects demand empirically validated treatment programs. more than a million veterans receive new diagnoses of each year. va ptsd therapy programs reach only 1% of veterans. nearly 35% of veterans do not respond to widely used psychotherapy and pharmacotherapy treatments. training a service dog (sd) is a novel rehabilitative animal-assisted intervention that shows promise in other populations. this project evaluates the efficacy of a service dog training program (sdtp) as an alternative and adjunctive treatment and rehabilitative option for veterans with ptsd.

veterans with ptsd attend 8 weekly sessions of either training a service dog or learning about how to train a dog at the warrior canine connection facility in boyds md. they complete questionnaires prior to the start of the program and at the midpoint (after 4 sessions) and end of the program (after 8 sessions). participants also wear a monitor to record heart rate variability during the 1st, 4th, and 8th sessions and provide saliva samples at these same times.

Eligibility criteria:
inclusion criteria 1. accepted into the warrior canine connection service dog training program. their inclusion criteria are: 1. military veteran; 2. diagnosis of ptsd; 3. able to give informed consent; and 4. able to understand english; and 2. military veteran exclusion criteria: excluded from the warrior canine connection service dog training program. their criteria are: 1. fear of dogs; 2. allergy to pet dander; 3. active substance abuse; 4. active psychosis, or 5. history of animal abuse 6. excluded by the wcc from participation in their service dog training program because they have: fear of dogs; allergy to pet dander; active substance abuse; active psychosis, history of animal abuse or physically unable to complete tasks required to train dogs .

Keywords: human-animal interaction service dog stress
effects of a multiple component training program on muscles in adults with myotonic dystrophy type 1

Conditions: Myotonic Dystrophy 1

Summary: a strength and endurance training program was conducted in adults with myotonic dystrophy type 1 (dm1). participants underwent a 12-week/18-session supervised training program consisted of 6 exercises: elbow flexion/extension, shoulder horizontal adduction, leg press, and knee flexion/extension. to offer a complete training program aimed at improving function it was divided: the first 6 weeks were dedicated to strength-training, whereas the following weeks focused on endurance-training. to evaluate the effects of the training program, participants completed maximal strength, endurance and functional evaluations. volunteers could also add a muscle biopsy at the beginning and the end of the program to evaluate physiological parameters.


Eligibility criteria:
inclusion criteria: * adults with dm1 * walk without technical aid * muscle impairment rating scale (mirs) of 3 or 4 exclusion criteria: * severe musculoskeletal disorders * any medical contraindication to physical exercise * any medical contraindication to muscle biopsies for the biopsy volunteers
effect of paracetamol and ketorolac on rank-l levels in patients starting orthodontic treatment

Conditions: Malocclusion; Pain, Acute

Summary: due to the high prevalence of malocclusions in mexico and the existing concern to improve aesthetics, function (chewing), or both, patients resort to orthodontic treatment. the patient may experience pain during treatment due to the release of different chemical mediators such as rank-l. analgesic and anti-inflammatory medications such as acetaminophen and ketorolac are used to control pain during orthodontic tooth movement. these drugs can inhibit the expression of rank-l which can affect tooth movement, inhibiting bone remodeling. the orthodontist should indicate the drug that is safest for the patient without affecting treatment or tooth movement.

objective: to evaluate the association of rank-l levels with the administration of paracetamol and ketorolac in patients starting orthodontic treatment. material and methods: a double-blind clinical trial will be carried out with a placebo control group and random drug allocation. patients who begin orthodontic treatment in the orthodontic specialty of the comprehensive dental clinics of the university center for health sciences and who decide to participate in the study with the signing of informed consent will be included. three groups will be formed with 8 patients in each one. the first group will be administered with placebo (calcined magnesia), the second group with ketorolac and the third group with paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled gingival crevicular fluid (lgc), visual analogue pain scale (aps) and intermolar space (is). measurements will be made four times; baseline, 24 h, 48 h, and on day 5 of initiation of treatment.

Eligibility criteria:
inclusion criteria: * patients of both sexes between 18 and 27 years of age * periodontally and systematically healthy * attended the orthodontic clinic of the university of guadalajara * who required the use of dental spacers in at least one quadrant were included exclusion criteria: * patients who have previously had orthodontic treatment or are under orthodontic treatment * who have an allergy to ketorolac or paracetamol * who are under pharmacological treatment and/or using contraceptives * pregnant or lactating women, as well as those who consume alcohol were not included or tobacco.

Keywords: orthodontics rank-l ketorolac paracetamol gingival crevicular fluid
effects of cocoa products on cardiovascular disease risk factors

Conditions: Cardiovascular Diseases

Summary: the purpose of this study is to evaluate the effects of optimized composition chocolates that include natural ingredients with demonstrated biological activity are observed cardioprotectores effects in the human.

studies carried out during the last decades have demonstrated of conclusive form that foods like nuts, products like cocoa or other ingredients, to be consumed of isolated form or when taking several from integrated them in a same diet can contribute to the prevention or the treatment of the cardiovascular diseases. the study was a randomized, controlled, double-blind, parallel multi-center study in which the 4 different types of cocoa products \[1)cocoa and other ingredients (sugar and vegetal oils), 2)cocoa plus hazelnuts and other ingredients, 3)the same as 2 plus other ingredient and 4) cocoa, hazelnuts and other ingredients called (lmn)\], introduced into a calorie-balanced diet for 4 weeks with a prior stabilization period of 2 weeks in which all participants received the cocoa product type 1. cocoa product type 1 is a control of type 2, and types 1 and 2 were controls of types 3 and 4. cocoa products type 4 is registered as patent. the trial was conducted in reus and 3 other cities in catalonia (alcover, centelles and vic) (spain).

Eligibility criteria:
inclusion criteria: * eligible participants had systolic blood pressure (bp) of 120 to 159 mm hg or a diastolic blood pressure of 80 to 99 mm hg. this range includes participants with prehypertension (systolic, 120-139 mm hg or diastolic, 80-89 mm hg) and stage 1 hypertension (systolic, 140-159 mm hg or diastolic, 90-99 mm hg). * moreover, participants' plasma ldl-cholesterol concentrations were ≥ 3.35 mmol/l (≥ 130 and ≤ 189 mg/dl) and triglyceride concentrations \< 4 mmol/l (350 mg/dl) in the fasting state and at least one cvd risk factor such as age (men ≥45 years; women ≥55 years), cigarette smoking, low high density lipoprotein cholesterol concentration (\<1.0 mmol/l (40 mg/dl) and \<1,18 mmol/l (46 mg/dl), men and women, respectively), family history of premature cvd (in male first-degree relative \<55 years of age, in female first-degree relative \<65 years of age. exclusion criteria: * assessed from the medical history and a complete physical examination, were plasma triglyceride concentrations ≥4 mmol/l (350 mg/dl), bmi \>35 kg/m2, cvd clinical events, use of lipid-lowering drugs at least 2 months prior to the start of study, diabetes mellitus (at least 2 fasting glucose ≥7.0 mmol/l (≥ 126 mg/dl), renal insufficiency, thyroid or other endocrine disease.

Keywords: cocoa cardiovascular disease blood pressure
evaluation of cardiac biomarkers and ventricular function in asthmatic children

Conditions: Ventricular Dysfunction; Asthma in Children

Summary: evaluation of cardiac biomarkers and the left and right ventricular systolic and diastolic function in asthmatic children in assuit university hospital

severe acute asthma which is defined asthma that is uncontrolled despite maximal optimized therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased(1) and it is characterized by severe respiratory distress because of increasing bronchoconstriction, leading to ventilation perfusion mismatch, hypoxia, respiratory muscle fatigue, carbon dioxide retention and respiratory acidosis(2) in acute severe asthma, the use of beta 2 agonists, together with hypoxia and tachycardia might cause increased myocardial workload further leading to myocardial infarction(3). cardiac biomarkers including brain natriuretic peptide (bnp),troponin i (tni) and creatine kinase muscle/brain(ck-mb) are used to detect myocardial injury(4). the objective of the present study was to find out the incidence of myocardial dysfunction in patients of acute severe bronchial asthma based on cardiac biomarker levels at admission and to see whether the myocardial dysfunction was transient or persistent even after the stabilization of the patient. as far as it could be reviewed, no study relating bnp levels in pediatric asthma patients could be found in literature. echocardiographic changes in bronchial asthma regarding rt ventricular and ltventricular function will be assessed according to some studies right ventricular (rv) systolic and diastolic dysfunction were detected, even in mild cases, by echocardiography. on the other hand, left ventricular (lv) dysfunction usually presents itself in severe asthmatic cases which may be reversible in acute conditions (5). some studies showed that there were no differences in echocardiographic findings regarding the ventricular function with the exception of rv wall thickness (6). asthma affects ventricular contractility in children. although cardiac systolic function was found to be impaired in asthmatic patients, contrary to the literature diastolic dysfunction didn't observed in these patients even by tissue doppler imaging, may be due to using inhaled corticosteroid(7). this was one of the most comprehensive studies among asthmatic patients. further studies with larger sample sizes or without using corticosteroid treatment war ranted to better elucidate the cardiac function.

Eligibility criteria:
inclusion criteria: * all pediatric cases between the age of 5 -15years with acute severe bronchial asthma who were admitted in pediatric emergency care unit exclusion criteria: * children with congenital or acquired heart diseases * foreign body aspiration . * chest infections * tuberculosis or pneumonia

Keywords: asthma cardiac affection
total glucosides paeony capsules in maintaining clinical remission in patients with ankylosing spondylitis which achieve clinical remission after anti-tnf therapy

Conditions: Ankylosing Spondylitis

Summary: this is a prospective, randomized, open-label clinical trial to evaluate the efficacy and safety of total glucosides paeony capsules in maintaining clinical remission in patients with ankylosing spondylitis which achieved clinical remission after anti-tnf therapy. patients will be divided into two groups randomly, one group receive non-steroid anti-inflammatory drugs(nsaid) mono-therapy and the other group receive total glucosides paeony capsules plus nsaid therapy for 24 weeks. the primary clinical endpoint is the proportion of patients which disease activity reaches relapse criteria. the investigator's hypothesis the proportion of relapse in total glucosides paeony capsules plus nsaid group would be lower than the nsaid mono-therapy group.


Eligibility criteria:
inclusion criteria: * aged from 16-65 years, sign the informed consent * fulfill 1984 modified newyork classification criteria for as * achieved clinical remission after at least 12 weeks' therapy of anti-tnf therapy * hb≥9g/dl, alt/ast≤ 2 folds of upper level normal range, creatine≤120mol/l(≤1.4mg/dl) * commitment to contraceptive for woman exclusion criteria: * history of psoriasis and/or inflammatory bowel diseases * receive intra-articular injection of cortisone within 3 months before enrollment * history of the listed diseases: heart failure, multiple sclerosis, severe chronic obstructive pulmonary disease, frequent infections, lymphoma or other cancers, tuberculosis * pregnant and lactating women * mentally ill, alcoholics and drug addicts
study of external beam radiation therapy with and without hormonal therapy to treat prostate cancer

Conditions: Prostate Cancer

Summary: this clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.

this was a randomized study comparing external beam radiation therapy with total androgen ablation for 6 months with radiation therapy alone. drugs were given 2 months prior, 2 months during, and 2 months after radiation therapy. eulexin and lupron or zoladex was used in this study.

Eligibility criteria:
inclusion criteria: * biopsy proven prostate cancer * negative bone scan * lymph nodes by ct or mri * adequate blood work * performance status - ecog 0-1 * life expectancy of at least 10 years * \>40 years of age exclusion criteria: * prior history of malignancy * prior hormonal therapy or chemotherapy * prior pelvic radiation therapy * unable to tolerate lying still 5-10 minutes/day

Keywords: prostate cancer total androgen suppression endorectal coil mri external beam radiation therapy prostate cancer- high risk, clinically organ-confined
the benchmark clinic: an interdisciplinary comprehensive care model for people with parkinson disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to determine if an interdisciplinary clinic can help people with parkinson's disease care for themselves, improve their ability to follow recommended treatments, and have fewer problems like falls or visits to the emergency room. participants will be randomly assigned to receive either care from the interdisciplinary clinic or standard neurological specialist care. this study involves questionnaires both before and 3 months after participation in a one time interdisciplinary care clinic or standard care depending on which type of care the participant is randomized to. participants will be in the study for up to 6 months. the study will end upon completion of questionnaires about 3 months after treatment with the interdisciplinary care clinic or standard care.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease over the age of 30, * caregiver willing to also participate. * must be able to provide consent. exclusion criteria: -atypical parkinsonism

Keywords: interdisciplinary care patient engagement preventative care
effect of inhaled ciclesonide in adult patients with asthma (by9010/m1-125)

Conditions: Asthma

Summary: ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. in this study the effect of ciclesonide on airway hyperresponsiveness (ahr), exhaled nitric oxide (no), and induced sputum inflammatory biomarkers will be evaluated.


Eligibility criteria:
main inclusion criteria: * out-patients * written informed consent * history of atopic disease * history of perennial bronchial asthma for at least 6 months as defined by ats criteria * current use of only inhaled short acting beta-2-agonist as required (for at least 4 weeks prior to baseline period b0) * stable asthma, i.e. no exacerbation or relevant respiratory tract infection within 2 months prior to study start * fev1 ≥ 70% predicted * hyperreactivity to amp (pc20fev1 \< 25 mg/ml) * good health with the exception of asthma * non-smokers as well as ex-smokers with either = 10 pack-years or more than 6 months of smoking abstinence main exclusion criteria: * concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids (e.g. lung tuberculosis) * clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation * use of systemic steroids 4 weeks (injectable depot steroids 6 weeks) before entry into the baseline period, or more than 3 times during the last 6 months * pregnancy or intention to become pregnant during the course of the study, breast feeding, lack of safe contraception in heterosexually active female patients of child-bearing potential, or postmenopausal for less than one year * copd (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases * known or suspected hypersensitivity to inhaled steroids or to the other excipients of the metered dose inhalers * immunotherapy within one month prior to b0 and/or during the entire study duration

Keywords: asthma ciclesonide airway hyperresponsiveness sputum nitric oxide